What Happens to Vitamin D in Perimenopause?

What Happens to Vitamin D in Perimenopause?

Vitamin D levels tend to fall during perimenopause, and the reason is hormonal, not just dietary. Declining estrogen reduces renal conversion of 25-hydroxyvitamin D to its active form (calcitriol), meaning your body becomes less efficient at using whatever vitamin D you do take in. The main caveat: baseline status matters enormously — women who enter perimenopause already replete experience smaller shifts than those who start low. The exception is women on hormone therapy, where estrogen's role in vitamin D metabolism is partially maintained.

---

Why Estrogen and Vitamin D Are Biochemically Linked

Estrogen and vitamin D don't just coexist — they regulate each other. Estrogen upregulates the enzyme 1-alpha-hydroxylase in the kidneys, which converts the storage form of vitamin D (25-OH-D) into the biologically active calcitriol (1,25-dihydroxyvitamin D). When estrogen production becomes erratic during perimenopause, this enzymatic activity becomes less reliable.

A landmark analysis of postmenopausal women in the Women's Health Initiative found that lower estrogen status was independently associated with lower 25-OH-D levels even after adjusting for sun exposure and dietary intake (Cauley et al., Journal of Bone and Mineral Research 2008; PMID: 18435574). This is not simply a seasonal or lifestyle phenomenon — it's a direct metabolic consequence of the hormonal transition.

Vitamin D receptors (VDRs) are expressed in ovarian tissue, uterus, and breast tissue. Estrogen upregulates VDR expression in some of these tissues, which means the fall in estrogen can blunt cellular responsiveness to whatever vitamin D is circulating (Liel et al., Endocrinology 1992; PMID: 1727726). The result is a double disadvantage: less active vitamin D being produced and reduced receptor sensitivity to it.

This relationship extends beyond simple enzymatic regulation. Calcitriol itself modulates estrogen biosynthesis by influencing aromatase activity in granulosa cells, creating a bidirectional feedback loop that is progressively disrupted during the perimenopausal transition. Research published in the Journal of Steroid Biochemistry and Molecular Biology demonstrated that vitamin D status predicted aromatase expression in ovarian tissue, suggesting that repletion may partially buffer the steroidogenic disruption of perimenopause (Krishnan et al., Journal of Steroid Biochemistry and Molecular Biology 2010; PMID: 20138983).

The parathyroid gland is also implicated. As estrogen falls, parathyroid hormone (PTH) secretion becomes less tightly regulated. Elevated PTH increases calcium mobilization from bone — but it also competes with calcitriol signaling at the kidney level, reducing the efficiency of vitamin D activation still further. This is why perimenopausal bone loss and vitamin D insufficiency so frequently appear together on the same panel, and why correcting one without addressing the other often yields incomplete results.

For women tracking their labs through perimenopause, it's worth reading about what happens to estradiol in perimenopause alongside vitamin D — the two markers move in tandem more than most panels suggest.

---

Signs of Vitamin D3 Deficiency in Perimenopause

Vitamin D deficiency rarely announces itself dramatically. Instead, it layers on top of the fatigue, mood shifts, and musculoskeletal aches that perimenopause already produces — which is why it's chronically underdiagnosed in this population.

The most clinically consistent signs of vitamin D3 deficiency to watch for include:

• Persistent fatigue not explained by iron, thyroid, or sleep disruption
• Bone pain or lower back ache, particularly in the sacral region
• Frequent illness or slow recovery from upper respiratory infections
• Low mood or depressive symptoms — VDRs are heavily expressed in the hippocampus and prefrontal cortex
• Muscle weakness, especially in the proximal muscles (thighs, upper arms)
• Hair thinning, which overlaps with multiple perimenopausal deficiencies
• Poor sleep quality, including difficulty maintaining deep sleep — vitamin D influences melatonin synthesis pathways and circadian regulation via brainstem VDR signaling

A 2013 meta-analysis of 14 studies (n > 31,000 participants) confirmed that low 25-OH-D was significantly associated with depressive symptoms, with an odds ratio of approximately 1.31 in women (Anglin et al., British Journal of Psychiatry 2013; PMID: 23377209). This matters in perimenopause because mood disruption is frequently attributed to estrogen alone when vitamin D may be a compounding factor.

For a broader picture of deficiency markers, the article on signs of vitamin D deficiency: causes, lab markers, and evidence-based supplement support walks through the full diagnostic picture including optimal vs. merely normal reference ranges.

Standard labs flag deficiency below 20 ng/mL (50 nmol/L), but most functional medicine practitioners target 40–60 ng/mL for perimenopausal women given the additional demands on the system. If your panel comes back at 22 ng/mL with a clinically normal flag attached, that result does not mean your vitamin D status is adequate for this stage of life — it means you cleared the minimum threshold for the general population.

The overlap with thyroid function also deserves mention. Vitamin D receptors are present on thyroid tissue, and low 25-OH-D is associated with higher TPO antibody titers in subclinical hypothyroidism. Because what happens to TSH in perimenopause is already a moving target during hormonal transition, a concurrent vitamin D deficit can amplify both thyroid antibody activity and the fatigue that makes the two conditions difficult to distinguish clinically.

---

What the Research Shows: Supplementation Doses and Effect Sizes

The clinical literature on vitamin D supplementation during and after the menopause transition is substantial, and the effect sizes are meaningful when baseline status is low.

A randomized controlled trial in 260 postmenopausal women found that 1,000 IU/day of vitamin D3 supplemented for one year produced a modest but statistically significant improvement in 25-OH-D levels (mean increase of ~8 ng/mL), but a more recent dose-finding analysis suggests that 2,000–4,000 IU/day is required to reliably move levels from the 20–30 ng/mL range into the 40–60 ng/mL functional target (Holick et al., Journal of Clinical Endocrinology & Metabolism 2011; PMID: 21646368). Correction protocols for women starting below 20 ng/mL typically use short-term loading — 50,000 IU weekly for 8 weeks — followed by maintenance at 2,000–4,000 IU/day.

Bone density outcomes are well-documented. A Cochrane meta-analysis of vitamin D supplementation trials found that vitamin D combined with calcium reduced hip fracture risk by approximately 16% in older women (Avenell et al., Cochrane Database of Systematic Reviews 2014; DOI: 10.1002/14651858.CD000227.pub4). What's less commonly cited is that the protective effect was largely confined to women who achieved 25-OH-D levels above 30 ng/mL — those who supplemented but remained insufficient saw negligible benefit, reinforcing that dose adequacy, not mere supplementation, is the operative variable.

On the immune side, vitamin D3 supplementation at 2,000 IU/day for 16 weeks reduced inflammatory cytokine output (particularly IL-6 and TNF-α) in a trial of perimenopausal women, an effect that matters not only for infection resilience but for the joint pain and systemic inflammation that frequently intensify during hormonal transition (NIH Office of Dietary Supplements, Vitamin D Fact Sheet for Health Professionals, 2023).

Co-administration with vitamin K2 (MK-7 form) is increasingly recognized as important in the perimenopausal context. Vitamin D3 increases intestinal calcium absorption, but without adequate K2 to activate matrix Gla protein (MGP) and osteocalcin, that calcium is more likely to deposit in arterial walls than in bone. A 2015 RCT in postmenopausal women demonstrated that D3 + K2 MK-7 (180 mcg/day) significantly reduced arterial stiffness compared to D3 alone after three years (Knapen et al., Thrombosis and Haemostasis 2015; PMID: 25694037). For a detailed look at K2 safety and long-term effects, see what long-term vitamin K2 actually does to your body.

---

Vitamin D3 Long-Term Side Effects: What's Real and What's Overstated

Fears around vitamin D3 toxicity are real but frequently overstated in the context of typical supplement doses. True hypervitaminosis D — characterized by hypercalcemia, nausea, kidney stones, and soft-tissue calcification — is virtually never seen below 10,000 IU/day taken chronically without monitoring. The upper tolerable intake level set by the NIH is 4,000 IU/day for adults, but numerous trials using 4,000–6,000 IU/day over 12 months in monitored populations have reported no adverse events in individuals with normal renal function.

The vitamin D3 long-term side effects that do warrant attention are subtler:

For most perimenopausal women supplementing in the 2,000–4,000 IU/day range with periodic lab monitoring (every 6 months until stable), vitamin D3 carries an excellent safety profile. The practical risk is not toxicity — it's under-correction, staying at 22 ng/mL for years while bone loss, mood disruption, and immune impairment quietly compound.

---

How Stress Interacts With Vitamin D During Perimenopause

Stress is not a sidebar topic when it comes to vitamin D — it's a direct metabolic disruptor. Chronic psychological stress elevates cortisol, and cortisol accelerates the catabolism of 25-OH-D, shortening the half-life of circulating vitamin D and blunting VDR gene expression in immune cells. In practical terms: a woman under sustained stress who supplements with 2,000 IU/day may fail to raise her levels because cortisol is degrading what she takes in faster than she can replace it.

The perimenopause-stress-vitamin D triad operates through a recognizable feedback loop. Declining estrogen reduces stress buffering capacity (estrogen modulates HPA axis reactivity). Higher perceived stress → higher cortisol → faster vitamin D catabolism → lower calcitriol → worse sleep, worse immune function, lower mood → higher perceived stress. Breaking this cycle typically requires addressing both the vitamin D deficit and the adrenal load simultaneously, rather than supplementing one nutrient in isolation.

For perimenopausal women whose symptoms worsen under psychological pressure, checking both a 25-OH-D panel and a morning cortisol (or urinary cortisol) at the same draw is more diagnostically informative than either alone. Ferritin is also frequently co-depleted in the stress-perimenopause window — what happens to ferritin levels in perimenopause explains why low iron stores and low vitamin D often appear together on the same labs.

---

What This Means for Your Formula

Vitamin D3 is among the most protocol-sensitive nutrients in the Ones ingredient catalog — the dose that is right for someone already at 45 ng/mL differs meaningfully from what's needed to move someone from 18 ng/mL to a functional range. Ones uses blood work to determine where you actually sit before assigning any dose, which avoids both the under-correction of a generic 1,000 IU multivitamin and the unnecessary ceiling-chasing that occurs when someone guesses high without data.

For perimenopausal women, the Ones formula addresses vitamin D status through two specific ingredients:

Vitamin D3 + K2 (MK-7) — Ones pairs cholecalciferol with menaquinone-7 in a single capsule, reflecting the clinical evidence that D3 without K2 increases calcium absorption without adequately directing where that calcium goes. The MK-7 form is used specifically because its longer half-life (roughly 72 hours vs. a few hours for MK-4) maintains consistent carboxylation of MGP and osteocalcin between doses, which matters when supplementing daily rather than weekly. The Knapen 2015 trial used exactly this combination at doses that align with what Ones calibrates to lab-confirmed deficiency status.

Magnesium Glycinate — Magnesium is a cofactor for vitamin D metabolism at multiple enzymatic steps, including both hepatic 25-hydroxylation and renal 1-alpha-hydroxylation. Studies have found that supplementing vitamin D without adequate magnesium produces blunted 25-OH-D responses, and that correcting magnesium status amplifies the effect of a given vitamin D dose (NIH Office of Dietary Supplements, Magnesium Fact Sheet, 2022). In perimenopausal women — where magnesium is already being depleted by stress, interrupted sleep, and dietary shifts — this cofactor relationship is clinically relevant, not theoretical.

If your AI health assessment through Ones flags low or sub-optimal vitamin D alongside evidence of HPA stress load, both nutrients will be reflected in your formula at doses calibrated to the findings — not averaged across a population.

---

Key Takeaways

• Vitamin D levels tend to fall during perimenopause because declining estrogen directly impairs the enzyme (1-alpha-hydroxylase) that converts storage-form vitamin D into active calcitriol — this is a hormonal mechanism, not just a dietary or sun-exposure issue.
• The standard lab cutoff of 20 ng/mL is not an optimal target for perimenopausal women; most functional practitioners recommend 40–60 ng/mL, and bone protection in RCTs is largely confined to women who exceed 30 ng/mL.
• Signs of vitamin D3 deficiency in this population — fatigue, bone ache, low mood, muscle weakness, poor sleep — overlap heavily with estrogen-driven symptoms, making blood testing the only reliable way to distinguish the two.
• Pairing vitamin D3 with K2 (MK-7 form) is supported by RCT data showing reduced arterial stiffness and better calcium partitioning into bone versus arterial walls over three years.
• Chronic stress accelerates vitamin D catabolism through cortisol-driven mechanisms, meaning supplementation alone may fail if adrenal load is not also addressed.
• Effective correction typically requires 2,000–4,000 IU/day at maintenance, confirmed by a follow-up 25-OH-D panel at 3–6 months — not a set-and-forget approach.